Mesenchymal stem cell-derived extracellular vesicles for human diseases
2024

Mesenchymal Stem Cell-Derived Extracellular Vesicles for Human Diseases

publication Evidence: high

Author Information

Author(s): Zhang Xiaofang, Che Xiaofang, Zhang Sibo, Wang Runze, Li Mo, Jin Yi, Wang Tianlu, Song Yingqiu

Primary Institution: Cancer Hospital of China Medical University

Hypothesis

The use of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) can enhance therapeutic outcomes for various human diseases.

Conclusion

MSC-EVs have shown potential in treating inflammatory diseases, tissue damage, tumors, and neurodegenerative disorders.

Supporting Evidence

  • MSC-EVs can reduce inflammation and promote tissue repair in diseases like rheumatoid arthritis and liver injury.
  • MSC-EVs have shown efficacy in modulating immune responses in COVID-19 patients.
  • MSC-EVs can deliver therapeutic miRNAs to target cells, enhancing their regenerative potential.

Takeaway

Scientists are studying tiny bubbles called extracellular vesicles from stem cells to help treat diseases like arthritis and COVID-19 without using whole stem cells.

Methodology

This review summarizes advances in the use of MSC-EVs in various diseases, focusing on their therapeutic effects and mechanisms.

Limitations

The short half-lives of EVs and the need for repeated treatments may limit their effectiveness.

Digital Object Identifier (DOI)

10.20517/evcna.2023.47

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication